Researcher Spotlight: Matthew Klairmont, MD NEW YORK UNIVERSITY SCHOOL OF MEDICINE In many cases, follicular lymphoma (FL) is an indolent and treatable B-cell lymphoma, and most patients live a normal lifespan. However, in a subset of patients, the disease can…
Researcher Spotlight: Tayla Foral, PhD DANA-FARBER CANCER INSTITUTE Mature T-cell lymphomas (TCL) are a highlyheterogeneous group of diseases with poor treatment options. Currently, many patients with TCL experience relapsed or refractory disease, and outcomes are generally poor. Dr. Foral’s LRF…
Researcher Spotlight: Robert Albero Gallego, PhD COLUMBIA UNIVERSITY Angioimmunoblastic T-cell lymphomas (AITLs) areaggressive forms of blood cancer and are often resistant to conventional chemotherapy. Certainmutations have been to be very common in AITLs, including mutations in the TET2 and RHOA…
Researcher Spotlight: Owhofasa Agbedia, MBBS, MPH UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Chimeric antigen receptor (CAR)-T cell therapies involve the re-engineering of a patient’s ownimmune cells to help them find and fight cancer cells within the body. This treatment…
Researcher Spotlight: Samuel Yamshon, MD JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY In recent years, there has been substantial research interest in harnessing the power of the body’s own immune system to help fight lymphoma. This type…
Researcher Spotlight: Harsh Shah, DO The University of Utah Stedman Family Scholar The future of lymphoma treatment is rapidly evolving, and investigator-initiated clinical trials are helping to pave the way toward improved treatment approaches. Dr. Shah’s LRF research is focused…
Researcher Spotlight: Helen Ma, MDStephanie A. Gregory Distinguished Scholar THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Veterans who have been involved in combat over the last several decades have been potentially exposed to a variety of carcinogenic elements, such as…
Researcher Spotlight: David Qualls, MD Memorial Sloan Kettering Cancer Center Immunotherapies in lymphoma aim to activate the patient’s own immune system to help target and destroy lymphoma cells. While effective, the impact of these types of therapies is often hampered…
Researcher Spotlight: Paola Ghione, MD MEMORIAL SLOAN KETTERING CANCER CENTER Lymphomas are a highly heterogeneous set of diseases, and while many people will do well with treatment, there are subsets of patients whose cancer does not respond or relapses quickly…
Researcher Spotlight: Dai Chihara, MD UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Phase I trials are the first step in transitioning new drugs from the bench to the clinic. These trials are intended to evaluate the safety and tolerability of…